Hanna Kim Gaggin, MD, MPH, FACC

Hanna Gaggin

General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Merck & Co., Inc.(SIGNIFICANT), Eko(MODEST), Amgen Inc.(SIGNIFICANT) OFFICER, DIRECTOR ETC: MGH Cardiology Board Review Book(MODEST) OWNERSHIP/PARTNERSHIP/PRINCIPAL: Eko(SIGNIFICANT) RESEARCH/RESEARCH GRANTS: Jana Care(SIGNIFICANT), Ortho Clinical(SIGNIFICANT), Novartis Corporation(SIGNIFICANT), Roche Diagnostics(SIGNIFICANT), Pfizer Inc(SIGNIFICANT), Alnylam(SIGNIFICANT), Akcea/Ionis(SIGNIFICANT) OTHER FINANCIAL BENEFIT: Baim Institute for Clinical Research (non-profit) for Abbott(SIGNIFICANT)

View Full Disclosure